查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1678737

Guillain-Barré二氏症候群診斷市場規模、佔有率、趨勢報告：按測試、最終用途、地區、細分市場預測，2025-2030

Guillain-Barre Syndrome Diagnostics Market Size, Share & Trends Report By Test (Lumbar Puncture, Electromyography), By End-use (Hospitals And Clinics, Diagnostic Laboratories), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

Guillain-Barré二氏症候群診斷市場的成長與趨勢

根據Grand View Research, Inc.的最新報告，全球Guillain-Barré二氏症候群診斷市場規模預計到2030年將達到1.699億美元，2025-2030年期間的複合年成長率為2.8%。

這主要是由於Guillain-Barré二氏症候群，尤其是在感染疾病率高的地區。感染疾病，包括呼吸道疾病和胃腸道疾病，通常領先，這增加了對有效診斷工具的需求。例如，明尼蘇達大學於 2023 年 10 月發表的一項研究發現，67% 的格林巴利症候群病例領先過此類感染疾病，凸顯了及時診斷的必要性。

診斷技術的進步也在市場擴張中發揮關鍵作用。肌電圖 (EMG) 和神經傳導研究的技術創新提高了格林-巴利綜合症診斷的準確性和速度。這些技術改進將使醫療專業人員能夠更早發現病情，從而促進更快的干涉並改善患者的治療效果。先進的診斷工具在臨床實踐中的整合正變得越來越普遍，體現了改善患者照護的承諾。

醫療保健專業人員和一般民眾對格林-巴利症候群的認知不斷提高，進一步推動了診斷市場的發展。加強教育力度和資訊傳播有助於更早發現症狀並進行後續診斷測試。這種認知的提升使患者能夠及時得到適當的治療，從而降低了因延遲診斷而導致嚴重併發症的風險。這導致對診斷服務的需求增加，促進了市場的成長。

老齡人口的成長正在影響GBS診斷市場。由於老年人更容易受到引發格林巴利症候群的感染疾病，因此需要採取有效的診斷措施。根據2021年世界衛生組織（WHO）的預測，到2030年，全球六分之一的人口將超過60歲，預計這一數字將從2020年的10億增加到2050年的21億。這種人口結構變化凸顯了可獲取且準確的診斷工具的重要性，因為預計老年族群中格林巴利症候群病例會增加。

市場的主要企業正在採取地理擴張、夥伴關係、夥伴關係和合資企業等策略性舉措，以增加其在市場中的佔有率。

Guillain-Barré二氏症候群診斷市場報告重點

  • 市場的測試部分包括腰椎穿刺、肌電圖、神經傳導測試等。腰椎穿刺部分將在 2024 年引領市場，佔據 45.1% 的最大收益佔有率，並且由於其在確認格林-巴利症候群診斷中的重要作用，預計在預測期內將實現 3.0% 的最快年複合成長率(CAGR)。
  • 最終用途部分包括醫院診所和診斷實驗室。 2024 年，醫院診所以 63.0% 的收入佔有率引領市場，透過整合先進的診斷工具和改進的病患管理通訊協定推動顯著成長。
  • 2024 年，亞太地區佔據全球市場主導地位，收益佔有率為 41.8%。認知的提高、醫療基礎設施的改善和診斷率的上升等因素正在推動市場擴張。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章Guillain-Barré二氏症候群診斷市場變數、趨勢與範圍

  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
    • 市場機會分析
  • Guillain-Barré二氏症候群診斷市場分析工具
    • 產業分析—波特五力分析
    • PESTEL 分析
    • COVID-19影響分析
    • 使用案例

第4章Guillain-Barré二氏症候群診斷市場：按測試、估計和趨勢分析

  • 2024年和2030年的測試市場佔有率
  • 細分儀表板
  • Guillain-Barré二氏症候群診斷市場的全球前景（按測試）
  • 腰椎穿刺
  • 神經傳導研究
  • 肌電圖
  • 其他

第5章Guillain-Barré二氏症候群診斷市場：按最終用途的估計和趨勢分析

  • 2024 年及 2030 年最終用途市場佔有率
  • 細分儀表板
  • Guillain-Barré二氏症候群診斷市場的全球前景（按最終用途）
  • 醫院和診所
  • 診斷實驗室
  • 其他

第 6 章Guillain-Barré二氏症候群診斷市場：區域估計和趨勢分析、按產品、按測試、按最終用途

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 全球區域市場概述
  • 2018-2030年市場規模、預測趨勢分析
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭格局

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 2024年主要企業的市場佔有率/地位分析
  • 公司簡介
    • Cadwell Industries, Inc
    • Natus Medical Incorporated
    • Nihon Kohden Corporation
    • Medtronic plc
    • Bionen Medical Devices
    • Deymed Diagnostic
    • Neurosoft
    • Alpine Biomed
    • EMS Biomedical
    • Rochester Electro-Medical, Inc
Product Code: GVR-4-68040-522-7

Guillain-Barre Syndrome Diagnostics Market Growth & Trends:

The global guillain-barre syndrome diagnostics market size is expected to reach USD 169.9 million by 2030, registering a CAGR of 2.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. driven by several key factors. A significant contributor is the increasing incidence of Guillain-Barre syndrome (GBS), particularly in regions with high rates of infectious diseases. Infections such as respiratory or gastrointestinal illnesses often precede GBS, leading to a heightened demand for effective diagnostic tools. For instance, a study from the University of Minnesota in October 2023 highlighted that 67% of GBS cases were preceded by such infections, underscoring the need for timely diagnosis.

Advancements in diagnostic techniques have also played a crucial role in market expansion. Innovations in electromyography (EMG) and nerve conduction studies have enhanced the accuracy and speed of GBS diagnosis. These technological improvements enable healthcare professionals to detect the syndrome earlier, facilitating prompt intervention and better patient outcomes. The integration of advanced diagnostic tools in clinical settings has become increasingly prevalent, reflecting a commitment to improving patient care.

The growing awareness of GBS among healthcare providers and the general population has further propelled the diagnostics market. Educational initiatives and increased information dissemination have led to earlier recognition of symptoms and subsequent diagnostic testing. This heightened awareness ensures that patients receive timely and appropriate care, reducing the risk of severe complications associated with delayed diagnosis. Consequently, the demand for diagnostic services has risen, contributing to market growth.

The expanding geriatric population has influenced the market for GBS diagnostics. Older individuals are more susceptible to infections that can trigger GBS, necessitating effective diagnostic measures. According to the World Health Organization's 2021 forecast, by 2030, one in six individuals worldwide will be over 60, with their numbers expected to grow from 1 billion in 2020 to 2.1 billion by 2050. This demographic shift underscores the importance of accessible and accurate diagnostic tools to manage the anticipated increase in GBS cases among the elderly.

Key players in the market are implementing strategic initiatives such as geographical expansion, collaborations, partnerships, and joint ventures to strengthen their market presence.

Guillain-Barre Syndrome Diagnostics Market Report Highlights:

  • The test segment of the market includes lumbar puncture, electromyography, nerve conduction studies, and others. The lumbar puncture segment led the market in 2024, accounting for the largest revenue share of 45.1%, and is expected to experience the fastest compound annual growth rate (CAGR) of 3.0% during the forecast period, driven by its essential role in confirming GBS diagnosis.
  • The end-use segment comprises hospitals & clinics, and diagnostic laboratories. In 2024, the hospitals & clinics segment led the market, capturing a revenue share of 63.0%, driving significant growth through the integration of advanced diagnostic tools and improved patient management protocols.
  • Asia Pacific dominated the global market with a revenue share of 41.8% in 2024. Factors such as rising awareness, improving healthcare infrastructure, and increasing diagnostic rates are driving market expansion.

Table of Contents

Chapter 1. Research Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Test
    • 1.1.2. End Use
    • 1.1.3. Regional scope
    • 1.1.4. Estimates and forecast timeline.
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database.
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
    • 1.6.2. Approach 1: Commodity flow approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Test outlook
    • 2.2.2. End use outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Guillain-Barre Syndrome (GBS) Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Dynamics
    • 3.1.1. Market driver analysis
    • 3.1.2. Market restraint analysis
    • 3.1.3. Market opportunities analysis
  • 3.2. Guillain-Barre Syndrome (GBS) Diagnostics Market Analysis Tools
    • 3.2.1. Industry Analysis - Porter's
      • 3.2.1.1. Supplier power
      • 3.2.1.2. Buyer power
      • 3.2.1.3. Substitution threat
      • 3.2.1.4. Threat of new entrant
      • 3.2.1.5. Competitive rivalry
    • 3.2.2. PESTEL Analysis
      • 3.2.2.1. Political landscape
      • 3.2.2.2. Economic landscape
      • 3.2.2.3. Social landscape
      • 3.2.2.4. Technological landscape
      • 3.2.2.5. Environmental landscape
      • 3.2.2.6. Legal landscape
    • 3.2.3. COVID-19 Impact Analysis
    • 3.2.4. Case Studies

Chapter 4. Guillain-Barre Syndrome (GBS) Diagnostics Market: Test Estimates & Trend Analysis

  • 4.1. Test Market Share, 2024 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Guillain-Barre Syndrome (GBS) Diagnostics Market by Product Test Outlook
  • 4.4. Lumbar Puncture
    • 4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.5. Nerve Conduction Studies
    • 4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.6. Electromyography
    • 4.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.7. Others
    • 4.7.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Guillain-Barre Syndrome (GBS) Diagnostics Market: End Use Estimates & Trend Analysis

  • 5.1. End Use Market Share, 2024 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Guillain-Barre Syndrome (GBS) Diagnostics Market by End Use Outlook
  • 5.4. Hospitals and Clinics
    • 5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 5.5. Diagnostic Laboratories
    • 5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 5.6. Others
    • 5.6.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Guillain-Barre Syndrome (GBS) Diagnostics Market: Regional Estimates & Trend Analysis, By Product, By Test, By End Use

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. Global Regional Market Snapshot
  • 6.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 6.5. North America
    • 6.5.1. U.S.
      • 6.5.1.1. Key country dynamics
      • 6.5.1.2. Regulatory framework/ reimbursement structure
      • 6.5.1.3. Competitive scenario
      • 6.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Canada
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Regulatory framework/ reimbursement structure
      • 6.5.2.3. Competitive scenario
      • 6.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. Mexico
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Regulatory framework/ reimbursement structure
      • 6.5.3.3. Competitive scenario
      • 6.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Europe
    • 6.6.1. UK
      • 6.6.1.1. Key country dynamics
      • 6.6.1.2. Regulatory framework/ reimbursement structure
      • 6.6.1.3. Competitive scenario
      • 6.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Germany
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Regulatory framework/ reimbursement structure
      • 6.6.2.3. Competitive scenario
      • 6.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.3. France
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Regulatory framework/ reimbursement structure
      • 6.6.3.3. Competitive scenario
      • 6.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.4. Italy
      • 6.6.4.1. Key country dynamics
      • 6.6.4.2. Regulatory framework/ reimbursement structure
      • 6.6.4.3. Competitive scenario
      • 6.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.5. Spain
      • 6.6.5.1. Key country dynamics
      • 6.6.5.2. Regulatory framework/ reimbursement structure
      • 6.6.5.3. Competitive scenario
      • 6.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.6. Norway
      • 6.6.6.1. Key country dynamics
      • 6.6.6.2. Regulatory framework/ reimbursement structure
      • 6.6.6.3. Competitive scenario
      • 6.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.7. Sweden
      • 6.6.7.1. Key country dynamics
      • 6.6.7.2. Regulatory framework/ reimbursement structure
      • 6.6.7.3. Competitive scenario
      • 6.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.8. Denmark
      • 6.6.8.1. Key country dynamics
      • 6.6.8.2. Regulatory framework/ reimbursement structure
      • 6.6.8.3. Competitive scenario
      • 6.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Asia Pacific
    • 6.7.1. Japan
      • 6.7.1.1. Key country dynamics
      • 6.7.1.2. Regulatory framework/ reimbursement structure
      • 6.7.1.3. Competitive scenario
      • 6.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.2. China
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Regulatory framework/ reimbursement structure
      • 6.7.2.3. Competitive scenario
      • 6.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. India
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Regulatory framework/ reimbursement structure
      • 6.7.3.3. Competitive scenario
      • 6.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. Australia
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Regulatory framework/ reimbursement structure
      • 6.7.4.3. Competitive scenario
      • 6.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.5. South Korea
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Regulatory framework/ reimbursement structure
      • 6.7.5.3. Competitive scenario
      • 6.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.6. Thailand
      • 6.7.6.1. Key country dynamics
      • 6.7.6.2. Regulatory framework/ reimbursement structure
      • 6.7.6.3. Competitive scenario
      • 6.7.6.4. Singapore market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Latin America
    • 6.8.1. Brazil
      • 6.8.1.1. Key country dynamics
      • 6.8.1.2. Regulatory framework/ reimbursement structure
      • 6.8.1.3. Competitive scenario
      • 6.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.8.2. Argentina
      • 6.8.2.1. Key country dynamics
      • 6.8.2.2. Regulatory framework/ reimbursement structure
      • 6.8.2.3. Competitive scenario
      • 6.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.9. MEA
    • 6.9.1. South Africa
      • 6.9.1.1. Key country dynamics
      • 6.9.1.2. Regulatory framework/ reimbursement structure
      • 6.9.1.3. Competitive scenario
      • 6.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.2. Saudi Arabia
      • 6.9.2.1. Key country dynamics
      • 6.9.2.2. Regulatory framework/ reimbursement structure
      • 6.9.2.3. Competitive scenario
      • 6.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.3. UAE
      • 6.9.3.1. Key country dynamics
      • 6.9.3.2. Regulatory framework/ reimbursement structure
      • 6.9.3.3. Competitive scenario
      • 6.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.9.4. Kuwait
      • 6.9.4.1. Key country dynamics
      • 6.9.4.2. Regulatory framework/ reimbursement structure
      • 6.9.4.3. Competitive scenario
      • 6.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 7.2. Company/Competition Categorization
  • 7.3. Key company market share/position analysis, 2024
  • 7.4. Company Profiles
    • 7.4.1. Cadwell Industries, Inc
      • 7.4.1.1. Company overview
      • 7.4.1.2. Financial performance
      • 7.4.1.3. Technology test benchmarking
      • 7.4.1.4. Strategic initiatives
    • 7.4.2. Natus Medical Incorporated
      • 7.4.2.1. Company overview
      • 7.4.2.2. Financial performance
      • 7.4.2.3. Technology test benchmarking
      • 7.4.2.4. Strategic initiatives
    • 7.4.3. Nihon Kohden Corporation
      • 7.4.3.1. Company overview
      • 7.4.3.2. Financial performance
      • 7.4.3.3. Technology test benchmarking
      • 7.4.3.4. Strategic initiatives
    • 7.4.4. Medtronic plc
      • 7.4.4.1. Company overview
      • 7.4.4.2. Financial performance
      • 7.4.4.3. Technology test benchmarking
      • 7.4.4.4. Strategic initiatives
    • 7.4.5. Bionen Medical Devices
      • 7.4.5.1. Company overview
      • 7.4.5.2. Financial performance
      • 7.4.5.3. Technology test benchmarking
      • 7.4.5.4. Strategic initiatives
    • 7.4.6. Deymed Diagnostic
      • 7.4.6.1. Company overview
      • 7.4.6.2. Financial performance
      • 7.4.6.3. Technology test benchmarking
      • 7.4.6.4. Strategic initiatives
    • 7.4.7. Neurosoft
      • 7.4.7.1. Company overview
      • 7.4.7.2. Financial performance
      • 7.4.7.3. Technology test benchmarking
      • 7.4.7.4. Strategic initiatives
    • 7.4.8. Alpine Biomed
      • 7.4.8.1. Company overview
      • 7.4.8.2. Financial performance
      • 7.4.8.3. Technology test benchmarking
      • 7.4.8.4. Strategic initiatives
    • 7.4.9. EMS Biomedical
      • 7.4.9.1. Company overview
      • 7.4.9.2. Financial performance
      • 7.4.9.3. Technology test benchmarking
      • 7.4.9.4. Strategic initiatives
    • 7.4.10. Rochester Electro-Medical, Inc
      • 7.4.10.1. Company overview
      • 7.4.10.2. Financial performance
      • 7.4.10.3. Technology test benchmarking
      • 7.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 North America Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 4 North America Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 5 U.S. Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 6 U.S. Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 7 Canada Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 8 Canada Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 9 Mexico Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 10 Mexico Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 11 Europe Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 12 Europe Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 13 UK Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 14 UK Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 15 Germany Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 16 Germany Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 17 France Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 18 France Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 19 Italy Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 20 Italy Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 21 Spain Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 22 Spain Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 23 Denmark Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 24 Denmark Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 25 Sweden Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 26 Sweden Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 27 Norway Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 28 Norway Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 29 Asia Pacific Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 30 Asia Pacific Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 31 Japan Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 32 Japan Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 33 China Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 34 China Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 35 India Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 36 India Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 37 Australia Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 38 Australia Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 39 South Korea Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 40 South Korea Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 41 Thailand Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 42 Thailand Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 43 Latin America Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 44 Latin America Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 45 Brazil Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 46 Brazil Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 47 Argentina Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 48 Argentina Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 49 MEA Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 50 MEA Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 51 South Africa Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 52 South Africa Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 53 Saudi Arabia Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 54 Saudi Arabia Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 55 UAE Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 56 UAE Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)
  • Table 57 Kuwait Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by test, 2018 - 2030 (USD Million)
  • Table 58 Kuwait Guillain-Barre syndrome (GBS) diagnostics market estimates and forecasts by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Guillain-Barre Syndrome (GBS) Diagnostics market outlook
  • Fig. 9 Guillain-Barre Syndrome (GBS) Diagnostics competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Guillain-Barre Syndrome (GBS) Diagnostics market driver impact
  • Fig. 15 Guillain-Barre Syndrome (GBS) Diagnostics market restraint impact
  • Fig. 16 Guillain-Barre Syndrome (GBS) Diagnostics market strategic initiatives analysis
  • Fig. 17 Guillain-Barre Syndrome (GBS) Diagnostics market: Test analysis
  • Fig. 18 Guillain-Barre Syndrome (GBS) Diagnostics market: Test outlook and key takeaways
  • Fig. 19 Clinical writing market estimates and forecast, 2018 - 2030
  • Fig. 20 Lumbar puncture market estimates and forecast, 2018 - 2030
  • Fig. 21 Nerve conduction studies market estimates and forecast, 2018 - 2030
  • Fig. 22 Electromyography market estimates and forecast, 2018 - 2030
  • Fig. 23 Others market estimates and forecast, 2018 - 2030
  • Fig. 24 Guillain-Barre Syndrome (GBS) Diagnostics market: End use movement analysis
  • Fig. 25 Guillain-Barre Syndrome (GBS) Diagnostics market: End use outlook and key takeaways
  • Fig. 26 Hospitals and clinics market estimates and forecast, 2018 - 2030
  • Fig. 27 Diagnostic laboratories market estimates and forecast, 2018 - 2030
  • Fig. 28 Global Guillain-Barre Syndrome (GBS) Diagnostics market: Regional movement analysis
  • Fig. 29 Global Guillain-Barre Syndrome (GBS) Diagnostics market: Regional outlook and key takeaways
  • Fig. 30 Global Guillain-Barre Syndrome (GBS) Diagnostics market share and leading players
  • Fig. 31 North America market share and leading players
  • Fig. 32 Europe market share and leading players
  • Fig. 33 Asia Pacific market share and leading players
  • Fig. 34 Latin America market share and leading players
  • Fig. 35 Middle East & Africa market share and leading players
  • Fig. 36 North America: SWOT
  • Fig. 37 Europe SWOT
  • Fig. 38 Asia Pacific SWOT
  • Fig. 39 Latin America SWOT
  • Fig. 40 MEA SWOT
  • Fig. 41 North America market estimates and forecasts, 2018 - 2030
  • Fig. 42 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 43 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 44 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 45 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 46 UK market estimates and forecasts, 2018 - 2030
  • Fig. 47 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 48 France market estimates and forecasts, 2018 - 2030
  • Fig. 49 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 50 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 51 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 52 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 53 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 54 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 55 China market estimates and forecasts, 2018 - 2030
  • Fig. 56 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 57 India market estimates and forecasts, 2018 - 2030
  • Fig. 58 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 59 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 60 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 61 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 62 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 63 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 64 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 65 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 66 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 67 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 68 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 69 Market share of key market players- Guillain-Barre Syndrome (GBS) Diagnostics market
  • Fig. 70 Key Company Categorization
  • Fig. 71 Company Market Share/Position Analysis, 2024
  • Fig. 72 Strategic Framework